Carlos H Barrios
Overview
Explore the profile of Carlos H Barrios including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
12602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Barrios C
Breast
. 2022 Feb;
62 Suppl 1:S3-S6.
PMID: 35219542
Breast cancer represents an urgent global priority. While this is a universal issue, and as the burden of the disease is increasing globally, current estimates indicate that in the next...
22.
Smeltzer M, Scagliotti G, Wakelee H, Mitsudomi T, Roy U, Clark R, et al.
J Thorac Oncol
. 2022 Feb;
17(5):651-660.
PMID: 35183774
Introduction: To evaluate the effects of the global coronavirus disease 2019 (COVID-19) pandemic on lung cancer trials, we surveyed investigators and collected aggregate enrollment data for lung cancer trials across...
23.
Werutsky G, Barrios C, Cardona A, Albergaria A, Valencia A, Ferreira C, et al.
Lancet Oncol
. 2021 Nov;
22(11):e488-e500.
PMID: 34735818
Challenges of health systems in Latin America and the Caribbean include accessibility, inequity, segmentation, and poverty. These challenges are similar in different countries of the region and transcend national borders....
24.
Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward
Barrios C, Werutsky G, Mohar A, Ferrigno A, Muller B, Bychkovsky B, et al.
Lancet Oncol
. 2021 Nov;
22(11):e474-e487.
PMID: 34735817
The increasing burden of cancer represents a substantial problem for Latin America and the Caribbean. Two Lancet Oncology Commissions in 2013 and 2015 highlighted potential interventions that could advance cancer...
25.
Weis L, Tolaney S, Barrios C, Barroso-Sousa R
NPJ Breast Cancer
. 2021 Sep;
7(1):120.
PMID: 34518552
Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as...
26.
Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios C, Morise M, et al.
J Thorac Oncol
. 2021 Jul;
16(11):1872-1882.
PMID: 34265434
Introduction: IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and ALK-negative (wild type [WT]) metastatic NSCLC with high programmed death-ligand 1...
27.
Rugo H, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios C, et al.
J Natl Cancer Inst
. 2021 Jun;
113(12):1733-1743.
PMID: 34097070
Background: In the phase III IMpassion130 study, atezolizumab plus nab-paclitaxel (A+nP) showed clinical benefit in advanced or metastatic triple-negative breast cancer patients who were programmed death-ligand 1 (PD-L1)+ (tumor-infiltrating immune...
28.
Lara Gongora A, Werutsky G, Jardim D, Nogueira-Rodrigues A, Barrios C, Mathias C, et al.
JCO Glob Oncol
. 2021 May;
7:649-658.
PMID: 33956499
Purpose: COVID-19 has affected cancer care worldwide. Clinical trials are an important alternative for the treatment of oncologic patients, especially in Latin America, where trials can be the only opportunity...
29.
Barrios C, Mano M
Am Soc Clin Oncol Educ Book
. 2021 Apr;
41:1-10.
PMID: 33830826
Cancer is an increasing and significant problem for both high- and low- and middle-income countries. Basic, translational, and clinical research efforts have been instrumental in generating the outstanding improvements we...
30.
Moreno-Aspitia A, Holmes E, Jackisch C, de Azambuja E, Boyle F, Hillman D, et al.
Eur J Cancer
. 2021 Mar;
148:287-296.
PMID: 33765513
Aim: To present the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial. Patients And Methods: 8381 patients with stage I-III HER2 positive breast cancer randomised to chemotherapy...